hotspot -WSS

hotspot

author：hotspot 2025-10-02 19:55:19 - browse：36

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Listen: Biogen's potential pivot, & Illumina's next chapter

WSS

Crinetics acromegaly drug succeeds in late

Crinetics acromegaly drug succeeds in late

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Listen: Biogen's potential pivot, & Illumina's next chapter

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

There’s a way to spot data fakery. All journals should be using it

leisure time

hotspot

Wikipedia

DIEP, the 'gold standard' of breast reconstruction, is under threat

How to protect patients from sexual assault

Cancer drug shortages should be causing more outrage

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Jerome Adams on the need for new antivirals for Covid

Extensive review finds private equity owners jack up cost of care

Medicare details structure of new drug price negotiation program

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Virginia high school admissions case could be legal follow

In rare move, senator releases unverified FBI source report alleging Biden bribe

focus

Listen: Biogen's potential pivot, & Illumina's next chapter

A new ‘biological computer' targets cancer while sparing healthy cells

Delta passengers in Vegas fall sick while waiting on flight in triple

There’s a way to spot data fakery. All journals should be using it

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

Stem cell treatment guidelines are released by FDA

entertainment

focus

hotspot

hotspot